They used a combination of a ALK inhibitor and a SRC inhibitor on 9 cell lines that had acquired ALK inhibitor resistance and on 2/3s there were significant results. In particular, they found that an SRC inhibitor, AZD0530 (saracatinib), when combined with an ALK inhibitor resulted in “near complete obliteration of cell viability”. AstraZeneca Appears to own saracatinib and had abandoned it at one point. However, in June 2013 AstraZeneca partnered with NIH’s National Center for Advancing Translational Sciences (NCATS) and made two of their compounds available for study, including saracatinib. Numerous phase 2 trials and at least one phase 3 trial have resulted. I have not found an FDA approval yet.
Two other SRC inhibitors were mentioned in the article 1) dasatinib produced by Bristol-Myers Squibb and sold under the trade name Sprycel and 2) KIN001-113.
Dasatinib apparently has significant side effects and is not considered a good candidate for combination therapy.
They found that when they used saracatinib on its own it had no effect on cancer growth.